Merrill Lynch retains UCB at buy

UCB NPV was retained by Merrill Lynch analyst Erica Whittaker at a buy rating with a €48 price objective after Pfizer reported better-than-expected third-quarter sales of UCB's Zyrtec. The company also has strong prospects with current growth driver Keppra for epilepsy and future growth driver Cimzia for Crohn's disease and rheumatoid arthritis. Shares of the Brussels, Belgium, pharmaceutical company were last traded at €50.2042.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.